Related Experiment Video
Updated: Feb 10, 2026

Oral Health Assessment by Lay Personnel for Older Adults
Published on: February 2, 2020
Concerns for Bleeding in the Elderly with the Use of Direct Oral Anticoagulants
Michelle Min1, Stephanie Sibicky2
1North Shore University Hospital, Manhasset, New York. At the time of writing, she was a pharmacy student at Northeastern University School of Pharmacy, Boston, Massachusetts.
Insights
Direct oral anticoagulants (DOACs) are alternatives to warfarin for atrial fibrillation. Limited safety data exist for older adults, especially regarding bleeding risks with these novel anticoagulants.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Direct oral anticoagulants (DOACs) have emerged as alternatives to warfarin for preventing cardioembolic complications in nonvalvular atrial fibrillation since 2010.
- Limited safety data, particularly concerning bleeding risks, are available for DOACs in elderly populations (≥75 years).
Purpose of the Study:
- To review the available literature on bleeding risks associated with each DOAC in older adults.
- To highlight the need for further safety data in this specific demographic.
Main Methods:
- Review of existing literature, including retrospective cohort studies, secondary analyses, and subgroup analyses.
- Focus on gastrointestinal, intracranial, and major bleeding events as defined by the International Society on Thrombosis and Haemostasis.
Main Results:
- Analysis of bleeding risks for individual DOACs in adults aged 75 and older.
- Identification of gaps in current safety data for DOACs in the elderly population.
Conclusions:
- Further research is crucial to establish comprehensive safety profiles of DOACs in older adults.
- Understanding specific bleeding risks is essential for optimizing anticoagulant therapy in the geriatric population.
Abstract:
Since Food and Drug Administration approval of dabigatran in 2010, direct oral anticoagulants (DOACs) have been alternatives to warfarin for patients who are at risk for cardioembolic complications of nonvalvular atrial fibrillation. Unfortunately, there are limited safety data available on the use of these newer agents in older adults, particularly risks of gastrointestinal, intracranial, and major bleeding (as defined by the International Society on Thrombosis and Haemostasis) in those 75 years of age and older. The purpose of this manuscript is to provide a review of available literature regarding the risk of bleeding in older adults for each DOAC based on available retrospective cohort, secondary, and subgroup analyses, and to highlight the need for additional safety information in this population.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Bleeding in Fresh Concrete
Bleeding can cause several issues in the concrete structure. Sometimes, the rising water gets trapped beneath large aggregate...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Oral Cavity
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
Directing Effect of Substituents: meta-Directing Groups
Oral Hypoglycemic Agents: Glinides

